hydrodolasetron

active metabolite of dolasetron

Also Known As:

1-H-indole-3-carboxylic acid, trans-octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; MDL 74156; MDL-74156; 1H-Indole-3-carboxylic acid, octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - hydrodolasetron: 2
    - Quinolizines: 1
      - hydrodolasetron: 2

Related Diseases

1.	Neoplasms (Cancer) 05/01/1999 - "The intent of this study was to obtain preliminary data on the pharmacokinetics of the active metabolite, hydrodolasetron, in cancer patients. " 05/01/1999 - "The pharmacokinetics of hydrodolasetron were studied after administration of a single intravenous infusion of 0.6 mg/kg (group I) or 1.8 mg/kg (group II) in 21 cancer patients participating in a randomized, double-blind, parallel-group, multicenter trial of the drug in patients receiving their first course of high-dose (>/=75 mg/m ( 2 ) ) cisplatin-containing chemotherapy. "
2.	Neuroblastoma 08/14/1992 - "In radioligand binding experiments, MDL 73147EF and MDL 74156 inhibited the binding of [3H]GR65630 to 5-hydroxy-tryptamine3 (5-HT3) binding sites on membranes prepared from NG108-15 neuroblastoma x glioma cells. " 08/14/1992 - "Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells."
3.	Glioma (Gliomas) 08/14/1992 - "In radioligand binding experiments, MDL 73147EF and MDL 74156 inhibited the binding of [3H]GR65630 to 5-hydroxy-tryptamine3 (5-HT3) binding sites on membranes prepared from NG108-15 neuroblastoma x glioma cells. " 08/14/1992 - "Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells."

Related Drugs and Biologics

1.	Serotonin 5-HT3 Receptor Antagonists
2.	Mesylates (Mesylate)
3.	Cisplatin (Platino)
4.	dolasetron (Anzemet)
5.	GR 65630

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Drug Therapy (Chemotherapy)